Phase III diabetes data give Intarcia (and doctors, patients) options
This article was originally published in Scrip
Intarcia chairman, president and CEO Kurt Graves has more options than ever for advancing his private company's implantable, once-yearly diabetes therapy ITCA 650 now that he has positive results in hand from the first two of four Phase III clinical trials.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.